Ascend Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ascend Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-45,525	Closed	-$4.49M	–	169
2018 Q2	$4.49M	Buy	+45,525	New	+$4.52M	0.21%	113
2016 Q2	–	Sell	-40,000	Closed	-$2.51M	–	142
2016 Q1	$2.51M	Sell	40,000 -10,000	-20%	-$665K	0.24%	80
2015 Q4	$4.71M	Buy	+50,000	New	+$4.64M	0.17%	109

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Ascend Capital's ALNY Position: Q3 2018 in Review

Ascend Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2018, closing a stake of 45,525 shares — an estimated $4.49M sold.

Ascend Capital first reported a position in ALNY in Q4 2015 and held it in 3 quarters. The position peaked at $4.71M in Q4 2015. 305 funds tracked by Wall St. Rank hold ALNY as of Q3 2018.

Ascend Capital reported no remaining Alnylam Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Ascend Capital sold 45,525 Alnylam Pharmaceuticals shares in Q3 2018, an estimated $4.49M.
Ascend Capital first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 3 quarters.
Ascend Capital's Alnylam Pharmaceuticals position peaked at $4.71M in Q4 2015.
305 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.